"I have not failed, I've just found 10,000 ways that won't work!" so said Thomas Edison in describing his journey to the incandescent light bulb. This quote seemed appropraite as Michael and Josh conclude their journey in the neuroendocrine space and discuss neuroendocrine carcinomas (and poorly differentiated metastatic neuroendocrine tumours). Sometimes when you working in the oncological world, we all feel a bit like Thomas Edison, pouring sweat and tears into research that doesn't live up to expectations. But much like Thomas Edison, each step in this journey could revolutionise humanity or oncology, much like the CDK4/6 inhibitors, immunotherapy or tyrosine kinase inhibitors.

But we aren't there yet. This week, Michael discusses the immunotherapy agent (Spartalizumab) while Josh goes old-school and discusses the TOPIC-NEC Japanese trial comparing etoposide and cisplatin (EP) to irinotecan and cisplatin (IP). Michael and Josh smell small cell similarities coming aboard the neuroendocrine express!

Links to studies discussed in this episode (subscription may be required):

TOPIC-NEC: https://jamanetwork.com/journals/jamaoncology/fullarticle/2795418

Immunotherapy (Spartalizumab): https://erc.bioscientifica.com/view/journals/erc/28/3/ERC-20-0382.xml

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.